https://scholars.lib.ntu.edu.tw/handle/123456789/639919
標題: | Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer | 作者: | JIN-YUAN SHIH Luo, Yung-Hung Chang, Gee-Chen Chang, John Wen-Cheng Wang, Chin-Chou Yang, Tsung-Ying Fang, Wei-Tse Shau, Wen-Yi |
關鍵字: | ALK; Lorlatinib; NSCLC | 公開日期: | 8-一月-2024 | 來源出版物: | Journal of the Formosan Medical Association = Taiwan yi zhi | 摘要: | Lorlatinib is a brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) inhibitor indicated for ALK-positive metastatic non-small cell lung cancer (NSCLC). In a global phase II study, patients who experience disease progression despite prior treatment with ALK tyrosine kinase inhibitors (TKIs) was assessed. Herein, we report real-world clinical outcomes of lorlatinib-treated patients with ALK-positive advanced NSCLC who were heavily pretreated and progressed on first- and second-generation ALK-TKIs, in a Taiwanese population under the lorlatinib expanded access program (EAP). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/639919 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2023.12.019 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。